Fortrea Holdings Inc. Common Stock FTRE
i
Market dataready · fetched 2026-11-12T15:56:50.356Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:56:22.850863095Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T15:56:49.833378+00:00
Fortrea Holdings Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 22.48 | 80.4% | 12.7% | 16.26 | 161.2% | 21.8% |
| 25Δ | 22.13 | 79.0% | 11.5% | 17.02 | 144.1% | 18.4% |
| 30Δ | 21.79 | 77.5% | 10.2% | 17.79 | 126.9% | 14.9% |
| 35Δ | 21.44 | 76.0% | 8.9% | 18.55 | 109.8% | 11.5% |
| 40Δ | 21.09 | 74.5% | 7.7% | 19.32 | 92.6% | 8.0% |
| 45Δ | 20.74 | 73.0% | 6.4% | 20.05 | 78.3% | 4.9% |
| 50Δ | 20.39 | 71.5% | 5.2% | 20.57 | 88.4% | 4.6% |
| 55Δ | 20.04 | 70.0% | 3.9% | 21.08 | 98.4% | 4.2% |
| 60Δ | 21.60 | 108.5% | 3.9% | |||
| 65Δ | 22.12 | 118.6% | 3.6% | |||
| 70Δ | 22.89 | 132.1% | 3.2% | |||
| 75Δ | 24.40 | 155.8% | 2.9% | |||
| 80Δ | 26.46 | 181.7% | 2.5% | |||
20Δ
- Pseudo strike
- 22.48
- IV
- 80.4%
- B/E move
- 12.7%
- Pseudo strike
- 16.26
- IV
- 161.2%
- B/E move
- 21.8%
25Δ
- Pseudo strike
- 22.13
- IV
- 79.0%
- B/E move
- 11.5%
- Pseudo strike
- 17.02
- IV
- 144.1%
- B/E move
- 18.4%
30Δ
- Pseudo strike
- 21.79
- IV
- 77.5%
- B/E move
- 10.2%
- Pseudo strike
- 17.79
- IV
- 126.9%
- B/E move
- 14.9%
35Δ
- Pseudo strike
- 21.44
- IV
- 76.0%
- B/E move
- 8.9%
- Pseudo strike
- 18.55
- IV
- 109.8%
- B/E move
- 11.5%
40Δ
- Pseudo strike
- 21.09
- IV
- 74.5%
- B/E move
- 7.7%
- Pseudo strike
- 19.32
- IV
- 92.6%
- B/E move
- 8.0%
45Δ
- Pseudo strike
- 20.74
- IV
- 73.0%
- B/E move
- 6.4%
- Pseudo strike
- 20.05
- IV
- 78.3%
- B/E move
- 4.9%
50Δ
- Pseudo strike
- 20.39
- IV
- 71.5%
- B/E move
- 5.2%
- Pseudo strike
- 20.57
- IV
- 88.4%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 20.04
- IV
- 70.0%
- B/E move
- 3.9%
- Pseudo strike
- 21.08
- IV
- 98.4%
- B/E move
- 4.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.60
- IV
- 108.5%
- B/E move
- 3.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.12
- IV
- 118.6%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.89
- IV
- 132.1%
- B/E move
- 3.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.40
- IV
- 155.8%
- B/E move
- 2.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.46
- IV
- 181.7%
- B/E move
- 2.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 79.92% | |
| 78.81% | |
| 78.04% | |
| 81.27% | |
| 79.28% | |
| 78.24% | |
| 77.99% | |
| 79.22% | |
| 75.78% | |
| 77.81% | |
| 77.07% | |
| 86.35% | |
| 89.35% | |
| 83.22% | |
| 95.36% | |
| 84.93% | |
| 84.01% | |
| 77.92% | |
| 81.83% | |
| 76.53% | |
| 77.41% | |
| 78.01% | |
| 76.90% | |
| 81.63% | |
| 75.54% | |
| 77.72% | |
| 81.89% | |
| 79.86% | |
| 81.51% | |
| 80.42% | |
| 76.91% | |
| 88.11% | |
| 96.39% | |
| 104.48% | |
| 80.19% | |
| 83.32% | |
| 81.72% | |
| 81.39% | |
| 83.05% | |
| 85.02% | |
| 87.16% | |
| 83.84% | |
| 85.53% | |
| 76.97% | |
| 77.11% |
Biotechnology
FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas…
More →GALT
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The…
More →GANX
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is…
More →GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
Description unavailable
More →